United Therapeutics
UTHR
308 hedge funds and large institutions have $7.74B invested in United Therapeutics in 2014 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 116 increasing their positions, 122 reducing their positions, and 45 closing their positions.
5% less repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 122
4% less funds holding
Funds holding: 321 → 308 (-13)
16% less capital invested
Capital invested by funds: $9.24B → $7.74B (-$1.5B)
22% less call options, than puts
Call options by funds: $13.7M | Put options by funds: $17.5M
22% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 45
58% less funds holding in top 10
Funds holding in top 10: 12 → 5 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.28B |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$107M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$53.6M |
| 4 |
AC
Amici Capital
New York
|
+$35M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Herndon Capital Management
Atlanta,
Georgia
|
-$144M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$138M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$74.3M |
| 4 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
-$73.8M |
| 5 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
-$27.3M |
UTHR Hedge Fund Activity: Q1 2014 in Review
308 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2014, worth a combined $7.74B — down 16% from $9.24B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of UTHR and 35 opened new positions — a net loss of 10 holders — while 122 trimmed existing stakes and 116 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $1.28B. The largest seller was Herndon Capital Management, cutting an estimated $144M.
- 308 institutional investors held United Therapeutics (UTHR) as of Q1 2014, down from 321 in Q4 2013.
- Funds reported $7.74B of United Therapeutics stock for Q1 2014, down 16% quarter-over-quarter.
- 35 funds opened new United Therapeutics positions in Q1 2014 and 45 closed out, a net change of -10 holders.
- The largest United Therapeutics buyer in Q1 2014 was BNP Paribas Financial Markets, an estimated $1.28B added.
- The largest United Therapeutics seller in Q1 2014 was Herndon Capital Management, an estimated $144M sold.
Based on aggregated 13F filings for Q1 2014.